These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 27621407)

  • 1. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
    LoRusso PM
    J Clin Oncol; 2016 Nov; 34(31):3803-3815. PubMed ID: 27621407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
    Gonzalez-Angulo AM; Blumenschein GR
    Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
    Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
    Markman B; Dienstmann R; Tabernero J
    Oncotarget; 2010 Nov; 1(7):530-543. PubMed ID: 21317449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
    Lim HJ; Crowe P; Yang JL
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
    Dienstmann R; Rodon J; Serra V; Tabernero J
    Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
    Cheaib B; Auguste A; Leary A
    Chin J Cancer; 2015 Jan; 34(1):4-16. PubMed ID: 25556614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PI3K-AKT-mTOR signaling network in cancer.
    Khan KH; Yap TA; Yan L; Cunningham D
    Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM
    Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.
    Wani AK; Singh R; Akhtar N; Prakash A; Nepovimova E; Oleksak P; Chrienova Z; Alomar S; Chopra C; Kuca K
    Mini Rev Med Chem; 2024; 24(16):1496-1520. PubMed ID: 38265369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.
    Patel S
    Curr Oncol Rep; 2013 Aug; 15(4):386-95. PubMed ID: 23605780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.
    Sacco A; Roccaro A; Ghobrial IM
    Oncotarget; 2010 Nov; 1(7):578-582. PubMed ID: 21317453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
    Pavlidou A; Vlahos NF
    ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.